MariMed Seeks Shareholder Approval for 1-for-50 to 1-for-100 Reverse Stock Split to Enable Uplisting
MRMD sits 29% above its 52-week low of $0.061.
Summary
MariMed filed a preliminary proxy seeking shareholder approval for a reverse stock split between 1-for-50 and 1-for-100 to facilitate a potential up-listing to NYSE American or Nasdaq. The special meeting is set for October 28, 2026.
Key Events · Corporate Governance and Compliance · MRMD
-
Reverse Stock Split Proposed
Board seeks approval to effect a reverse split at a ratio between 1-for-50 and 1-for-100, with the exact ratio to be set by the Board in its sole discretion.
-
Special Meeting Scheduled
Stockholders will vote on the proposal at a virtual special meeting on October 28, 2026, with a record date of September 4, 2026.
-
Uplisting as Primary Goal
The stated purpose is to raise the share price to meet minimum bid requirements for a potential listing on NYSE American or Nasdaq.
-
Federal Cannabis Hurdle
The filing acknowledges that adult-use cannabis remains illegal under U.S. federal law, and national exchanges have not listed companies engaged in adult-use cannabis activities, making uplisting uncertain.
Analysis · MRMD · Life Sciences
MariMed is asking shareholders to approve a reverse stock split at a ratio between 1-for-50 and 1-for-100, with the exact ratio left to the Board's discretion. The stated purpose is to raise the share price to meet minimum bid requirements for a potential up-listing to NYSE American or Nasdaq. The stock currently trades around $0.0788, well below the typical $2-$4 minimum bid thresholds. A reverse split would reduce the 403.7 million outstanding shares to between 4.0 million and 8.1 million shares, mechanically increasing the per-share price. However, the filing itself acknowledges that adult-use cannabis remains illegal under U.S. federal law, and national exchanges have not listed companies engaged in adult-use cannabis activities — meaning the uplisting path is uncertain even if the split is approved. The Board retains discretion to abandon the split entirely. This is a governance event with real implications for liquidity, institutional access, and the company's ability to raise capital, but it is not a completed transaction and carries significant execution risk.
How filings like this one have moved
In the 30 days to Sep 13, 2026, 29.4% of the 1723 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was -0.20%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, MRMD was trading at $0.08 on OTC in the Life Sciences sector, with a market capitalization of approximately $31.8M. The 52-week trading range was $0.06 to $0.18. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.